Table 1.

Relationship between expression levels of JWA and clinicopathologic features of the individuals in 3 cohorts of gastric cancers treated with surgery alone

VariablesTraining cohort (n = 80 cases)Testing cohort (n = 374 cases)Validation cohort (n = 385 cases)
Low (%)High (%)PaLow (%)High (%)PaLow (%)High (%)Pa
All patients50 (62.5)30 (37.5)166 (44.4)208 (55.6)195 (50.6)190 (49.4)
Age, y0.0510.3310.182
 ≤6543 (86.0)20 (66.7)111 (66.9)129 (62.0)92 (47.2)76 (40.0)
 >657 (14.0)10 (33.3)55 (33.1)79 (38.0)103 (52.8)114 (60.0)
Gender0.5950.4420.225
 Males36 (72.0)24 (80.0)112 (67.5)148 (71.2)145 (74.4)152 (80.0)
 Females14 (28.0)6 (20.0)54 (32.5)60 (28.8)50 (25.6)38 (20.0)
Depth of invasion0.0630.0040.040
 T1/T21 (2.0)4 (13.3)21 (12.7)51 (24.5)55 (28.2)73 (38.4)
 T3/T449 (98.0)26 (86.7)145 (87.3)157 (75.5)140 (71.8)117 (61.6)
Lymph node metastasis<0.001<0.0010.003
 N00 (0.0)20 (66.7)21 (12.7)83 (39.9)60 (30.8)87 (45.8)
 N1/N2/N350 (100.0)10 (33.3)145 (87.3)125 (60.1)135 (69.2)103 (54.2)
Distant metastasis0.0010.8200.259
 M035 (70.0)30 (100.0)158 (95.2)199 (95.7)186 (95.4)186 (97.9)
 M115 (30.0)0 (0.0)8 (4.8)9 (4.3)9 (4.6)4 (2.1)
TNM stage<0.001<0.0010.001
 I0 (0.0)9 (30.0)5 (3.0)35 (16.8)38 (19.5)56 (29.5)
 II3 (6.0)15 (50.0)25 (15.0)56 (26.9)38 (19.5)51 (26.8)
 III29 (58.0)4 (13.3)104 (62.7)94 (45.2)110 (56.4)82 (43.2)
 IV18 (36.0)2 (6.7)32 (19.3)23 (11.1)9 (4.6)1 (0.5)
Tumor diameter0.495<0.0010.124
 ≤5 cm24 (48.0)17 (56.7)47 (28.3)104 (50.0)101 (51.8)114 (60.0)
 >5 cm26 (52.0)13 (43.3)119 (71.7)104 (50.0)94 (48.2)76 (40.0)
Histologic typeb0.021<0.001<0.001
 Intestinal21 (42.0)21 (70.0)71 (42.8)141 (67.8)58 (29.7)100 (52.6)
 Diffuse29 (58.0)9 (30.0)95 (57.2)67 (32.2)135 (69.2)89 (46.8)
XRCC1 expression<0.001<0.001<0.001
 Low44 (88.0)7 (23.3)143 (86.1)34 (16.3)113 (57.9)70 (36.8)
 High6 (12.0)23 (76.7)23 (13.9)174 (83.7)82 (42.1)120 (63.2)
  • aTwo-sided Fisher exact tests.

  • bExcluded 3 patients with mixed intestinal and diffuse types in validation cohort.